003020 Stock Overview
Engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 003020 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Hefei Lifeon Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥18.22 |
| 52 Week High | CN¥23.87 |
| 52 Week Low | CN¥13.74 |
| Beta | 0.21 |
| 1 Month Change | -5.10% |
| 3 Month Change | -0.49% |
| 1 Year Change | -20.98% |
| 3 Year Change | -16.38% |
| 5 Year Change | n/a |
| Change since IPO | 10.93% |
Recent News & Updates
Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 05
Hefei Lifeon Pharmaceutical (SZSE:003020) Has A Somewhat Strained Balance Sheet
Sep 30Recent updates
Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 05Hefei Lifeon Pharmaceutical (SZSE:003020) Has A Somewhat Strained Balance Sheet
Sep 30Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50
May 23Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump
May 22Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues
Apr 29Shareholder Returns
| 003020 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.9% | -1.7% | -1.0% |
| 1Y | -21.0% | -4.3% | 10.8% |
Return vs Industry: 003020 underperformed the CN Pharmaceuticals industry which returned -4.3% over the past year.
Return vs Market: 003020 underperformed the CN Market which returned 10.8% over the past year.
Price Volatility
| 003020 volatility | |
|---|---|
| 003020 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 003020 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 003020's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,315 | Huanxi Cui | www.lifeonapi.com |
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients. It operates through Pharmaceutical Industry, Pharmaceutical Wholesale and Distribution, and Pharmaceutical Retail Business segments. The company offers active pharmaceutical ingredients, which include nifedipine, paliperidone, prilocaine, methylphenidate hydrochloride, dimercaptosuccinic acid, doxazosin mesylate, paeonol, urea, felodipine, and troxerutin; and medical preparations, such as osmotic pump preparations, central nervous systems, Chinese patent medicines, eye drops, external use, and general oral medicines.
Hefei Lifeon Pharmaceutical Co., Ltd. Fundamentals Summary
| 003020 fundamental statistics | |
|---|---|
| Market cap | CN¥3.48b |
| Earnings (TTM) | CN¥174.28m |
| Revenue (TTM) | CN¥1.50b |
20.0x
P/E Ratio2.3x
P/S RatioIs 003020 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 003020 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.50b |
| Cost of Revenue | CN¥455.13m |
| Gross Profit | CN¥1.05b |
| Other Expenses | CN¥871.99m |
| Earnings | CN¥174.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 69.69% |
| Net Profit Margin | 11.61% |
| Debt/Equity Ratio | 3.1% |
How did 003020 perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield46%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 09:18 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hefei Lifeon Pharmaceutical Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Feifei Xu | China Merchants Securities Co. Ltd. |
| Tielin Chen | Topsperity Securities |
| Xinming Zhou | Topsperity Securities |